BRNL CoreShares **Brent Oil** ETC

Leverage Shares

Investment Objective

The CoreShares Brent Oil ETC is a fully collateralised, UCITS eligible Exchange-Traded Commodity (ETC) designed to reflect the daily changes (in percentage terms) of the spot price of Brent Crude Oil as measured by the changes in the price of Brent Crude Oil future contracts as described in the LS Brent Crude Strategy, less expenses.

LS Brent Crude Strategy

The LS Brent Crude Strategy is designed as a systematic strategy to provide investors with a total return exposure to Brent Crude Oil Futures that are continuously rolled on a pre-determined rolling schedule starting on the sixth Futures Exchange Business Day of the relevant roll month. The Portfolio Administrator may, however, deviate from this strategy and/or invest in related Brent ETPs to deal with market disruptions or to improve the liquidity and tracking of the CoreShares Brent Oil ETC.

Key Benefits

- Low cost ETC exposure to Brent Crude Oil.
- Earn a return on the cash held referencing benchmark rates.
- Trade with your local broker in multiple currencies (no FX charges).
- Physically-backed: Underlying assets held, no swaps or OTC derivatives.
- Liquid. Trades on exchange, with multiple market makers providing intraday liquidity.
- Simple to trade: like any other stock – but simpler (no need for W-8BENs).

Key Risks

- Highly concentrated in one commodity. Commodity prices and futures may experience high volatility and are not appropriate for all investors.
- Investors can lose the full value of their initial investment (but not more).
- Daily changes in the price of the ETC may not closely track daily changes in the spot price of WTI Crude Oil, as the spot price is not in itself investable.
- Please see the 'Risks Factors' section of the Prospectus for a more detailed discussion of the potential risks associated with an investment in this product.

Product Information

Product Name	**CoreShares Brent Oil ETC**
Underlying	**Brent Crude Oil Futures and cash***
Strategy Tracked	**LS Brent Crude Strategy**
Replication	**Physical**
Base Currency	**USD**
ISIN	**XS2691037282**
Structure / Legal Form	**ETC / Debt Security**
Countries Available	**United Kingdom, Italy, Germany, France, Spain, Netherlands, Ireland, Poland, Belgium, Austria**
Issuer	**Leverage Shares PLC**
Trustee	**Apex Corporate Trustees (UK) Ltd**
Margin Provider / Stock Lender	**Interactive Brokers LLC and/or Morgan Stanley & Co. LLC**
Annual Management Fee	**0.35%**
SIPP/ISA Eligible	**Yes**

**This product may invest in related ETPs to improve tracking and liquidity of the Strategy.*

Country	Exchange	Base Currency	Trading Currency	Exchange Code	ISIN	SEDOL	BBG Ticker	RIC	WKN	Listing Date
UK	London Stock Exchange	USD	USD	1BRN	XS2691037282	BR53KY6	1BRN LN	1BRN.L	N/A	08/11/2023
UK	London Stock Exchange	USD	GBx	BRNL	XS2691037282	BR53L54	BRNL LN	BRNL.L	N/A	08/11/2023
Italy	Borsa Italiana	USD	EUR	BRENT	XS2691037282	N/A	BRENT IM	BRENT.MI	N/A	29/04/2024

Contact Information

Contact us at via email at info@leverageshares.com or on Twitter at @LeverageShares. More information on Leverage Shares can we found online at www.leverageshares.com .

Disclaimer

Please consult an investment adviser to determine whether or not the products are suitable for you. Traders should also review the Relevant Prospectus (as defined below) and the Leverage Shares educational materials carefully before considering the ETPs.

No investment advice

Leverage Shares PLC is required by the FCA to clarify that it is not acting for you in any way in relation to the investment or investment activity to which this financial promotion relates. In particular, LEVERAGE SHARES PLC will not provide any investment services to you and/or advise you on the merits of, or make any recommendation to you in relation to, the terms of any transaction. No representative of LEVERAGE SHARES PLC is authorised to behave in any way which would lead you to believe otherwise. LEVERAGE SHARES PLC is not, therefore, responsible for providing you with the protections afforded to its clients and you should seek your own independent legal, investment and tax or other advice as you see fit.

No offer for sale

The information contained in this financial promotion is neither an offer for sale nor a solicitation of an offer to buy securities. This financial promotion should not be used as the basis for any investment decision.

Risk Warnings

The value of an investment in ETPs may go down as well as up and past performance is not a reliable indicator of future performance. An investment in ETPs is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETPs offering daily leveraged or daily short exposures ("Leveraged ETPs") are products which feature specific risks that prospective investors should understand before investing in them.

Securities issued by the Issuer are products involving a significant degree of risk and may not be suitable for all types of investor. Any decision to invest should be based on the information contained in the Relevant Prospectus of the Issuer (or any supplements thereto) which includes, inter alia, information on certain risks associated with an investment. The price of any securities may go up or down and an investor may not get back the amount invested. Securities are priced in US Dollars/Euros/Pounds and the value of the investment in other currencies will be affected by exchange rate movements.

Short and leveraged exchange-traded products are only intended for investors who understand the risks involved in investing in a product with short and/or leveraged exposure and who intend to invest on a short-term basis. Any investment in short and/or leveraged products should be monitored on a daily basis to ensure consistency with your investment strategy. You should understand that investments in short and/or leveraged exchange-traded products held for a period of longer than one day may not provide returns equivalent to the return from the relevant unleveraged investment multiplied by the relevant leverage factor.

Please refer to the section entitled "Risk Factors" in the Relevant Prospectus for further details of these and other risks associated with an investment in exchange-traded products. You should consult an independent investment adviser prior to making an investment in exchange-traded products in order to determine its suitability to your circumstances.

Prospectus

A base prospectus has been approved by the Central Bank of Ireland as competent authority under Regulation (EU) 2017/1129 with respect to the offer and listing of ETPs in Ireland and certain other EU jurisdictions listed below (the "EU Prospectus"). A base prospectus has been approved by the Financial Conduct Authority as competent authority under the United Kingdom's version of Regulation (EU) No 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 with respect to the offer and listing of ETPs in the United Kingdom (the "UK Prospectus"). The "Relevant Prospectus" means the EU Prospectus or the UK Prospectus, as applicable.

The Central Bank of Ireland has delivered to the regulators listed below certificates of approval attesting that the EU Prospectus has been drawn up in accordance with Article 25 of Regulation (EU) 2017/1129.

The EU Prospectus (and any supplements thereto) of the Issuer has been passported from Ireland into Italy (Commissione Nazionale per la Societá e la Borsa), Germany (Bundesanstalt für Finanzdienstleistungsaufsicht), France (Autorité des Marchés Financiers), Spain (Comisión Nacional del Mercado de Valores), the Netherlands (the Autoriteit Financiële Markten), Poland (Komisja Nadzoru Finansowego), Belgium (Belgian Financial Services and Markets Authority) and Austria (Finanzmarktaufsichtsbehörde).

Investors should read the Relevant Prospectus of the Issuer before investing and should refer to the section of the Relevant Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in this product.